GlassScriptPhysician profile
Douglas C Cline
NPI 1619934858
$2,270.93
in general payments reported to CMS, 2019-2025
22 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $329 · 2021: $244 · 2022: $392 · 2023: $353 · 2024: $398 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $479.85 | 2019-2025 | Xtampza, Belbuca |
| Antares Pharma, INC. | $424.31 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $282.42 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $247.68 | 2019-2021 | |
| Abbvie INC. | $182.44 | 2022-2025 | Qulipta |
| Grt US Holding, INC. | $84.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $74.85 | 2019-2022 | |
| Spr Therapeutics, INC | $72.47 | 2023 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $63.05 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $54.25 | 2024 | |
| Novo Nordisk INC | $42.58 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.45 | 2022 | |
| Scilex Pharmaceuticals INC. | $35.83 | 2019-2024 | |
| Biodelivery Sciences International, INC. | $35.47 | 2019-2021 | |
| Daiichi Sankyo INC. | $30.69 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.83 | 2019-2021 | |
| Halozyme INC | $20.37 | 2023 | |
| Horizon Therapeutics Plc | $17.60 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.32 | 2019 | |
| International Rehabilitative Sciences, INC | $13.96 | 2024 | Rs 4i Plus Sequential Stimulator |
| Azurity Pharmaceuticals, INC. | $13.51 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Cline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.